At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 364 enrolled
Drug / intervention
American ginseng +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
In Brief
A Phase 3 clinical trial evaluating American ginseng and placebo for Chronic Myeloproliferative Disorders and 9 related conditions. Completed, enrolled 364 participants across 326 sites.
Detailed Summary
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartOct 2008
Primary CompletionAug 2011
Study CompletionAug 2013
TodayJul 2026
First PostedJul 21, 2008
Enrollment StartOct 1, 2008
Primary CompletionAug 1, 2011
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago
Interventions
American ginsengdrug
Given orally
placeboother
Given orally